

**We need system innovation in life
science and society as a whole.
But how?**






**Precision medicine
provides
opportunities**




Prevention + precision = sustainable precision health

Well-being




Physical and mental health.

Function / Capacity



Capacity to live a full and meaningful life and to contribute to society.

Cost





Sustainability and equity in health

Challenges on the way

- Policy
- Data
- Coordination
- Competences
- Competitive scale

What are we doing in Sweden to adress systemic challenges within life science?



ESS & MAX IV

THE EUROPEAN SPALLATION SOURCE (ESS)

ESS is one of the largest science infrastructure projects being built in Europe today. Designed to generate neutron beams for science, ESS will benefit a broad range of research, from life science to engineering materials, from heritage conservation to magnetism.

The facility design includes a 5 MW linear proton accelerator, a rotating tungsten target station, 22 state-of-the-art neutron instruments, a suite of laboratories, and a supercomputing data management and software centre.

Organized as a European Research Infrastructure Consortium, or ERIC,

MAX IV LABORATORY

MAX IV Laboratory has operated successfully for more than 30 years and is currently commissioning the new MAX IV synchrotron facility in Lund. Fully developed it will receive more than 2 000 scientists annually, from Sweden and the rest of the world. They will do research in areas such as materials science, structural biology, chemistry and nanotechnology. 200 people are currently employed at the MAX IV Laboratory. MAX IV is the largest and most ambitious Swedish investment in national research infrastructure. It is the brightest source of x-rays worldwide when inaugurated in June 2016. MAX IV Laboratory is hosted by Lund University. [Link to MAX IV](#)



[Videos & Presentations](#)

[Grants](#)

[Funding Guide](#)

[The Foundation](#)

[Press](#)



SEK 3.7 billion funding for life science – Knut and Alice Wallenberg Foundation launches a new research initiative

Press release
2020-10-20



Aktuellt från Swelife




Drop-in counseling for the call Collaboration projects for better health

Medtech4Health and Swelife invite to open drop-in counselling for our joint call for Collaborative projects for better health, autumn 2020. We keep Teams open during the times below, and then you have the opportunity to connect and get advice about...



New members and chair of the board for Swelife

Eva Sjökvist Saers has been chosen as the new chair of the strategic innovation programme Swelife in connection with the first board meeting of the year. At the meeting, a new board was also appointed, in accordance with the previously...




Glossary and method book for 'smarter' cancer care complete

To be able to use data in a smart and efficient way, it is not always possible to keep doing things the way they have always been done. For example, computers need help to understand us, and that is why...



WELCOME TO ATMP SWEDEN!



SWElife

'ATMP Sweden' is the national network of Sweden's activities within medicines based on genes, cells or tissue engineering, classified as Advanced Therapy Medicinal Products (ATMPs) in Europe. Our goal is to promote the collaboration and communication needed for accelerated, effective ATMP based patient solutions.

WHO ARE WE?

CAMP >

Join our experts in the science and technology for GMP compliant clinical translation of ATMP research.

Swelife-ATMP >

Join our experts in the knowledge, processes and competencies for getting ATMPs to patients.

ATMP Innovation Milieu >

Work with us towards making 'Sweden a world leader in advanced therapies by 2030'

Genomic Medicine Sweden



GMS – a unique collaboration between healthcare, academia & research infrastructure

SciLifeLab

Healthcare

Academia



+



+



Clinical Genomics Facilities

Genomic Medicine Sweden

2014

Clinical Genomics Uppsala
Clinical Genomics Stockholm

2016

Clinical Genomics Gbg
Clinical Genomics Lund

2017

GMS launched

2018

GMS national
funding by
Vinnova

2019

GMC formers
Clinical
Genomics
Linköping,
Umeå, Örebro

2020

GMS stage 2
funded

VINNOVA



OCTOBER 23, 2020

Day 2: Lights, Camera and Action – Upstream in bioreactor with cameras, sample analytics, in-bag sensors, parallel shake flask reactors and in-line mass spectrometry



TESTA CENTER IN 100 WORDS

We offer businesses and academia globally a modern, pilot-scale testbed for projects and education in production of biological products e.g. monoclonal antibodies, peptides, protein, vaccine and viral vectors (non-GMP, up to Bio-safety level 2 and 500 liter).

In our flexible facility, and with some helping hands of our experienced staff, you can perform a wide variety of projects, including scale-up of parts of a process, or a complete process from frozen cell bank vial to purified protein.

Testa Center is a major initiative between the Swedish government and Cytiva (formerly GE Life Sciences) to secure the growth of life science industry and its manufacturing capabilities. Main objective for Testa Center is to bridge the gap from discovery to industrialization.

Testa Center is operated as a non-profit company, owned by Cytiva.

Framtidens teknik i omsorgens tjänst

*Betänkande av
Utredningen om välfärdsteknik i äldreomsorgen*

Stockholm 2020

Welfare technologies

Suggests to government to initiate strategic innovation programme for welfare technologies.



Policy Infrastructure Ecosystems

Thank you!



Vinnova.se



/Vinnova



@Vinnovase



/Vinnovase